SG49653A1 - Dna sequences recombinant dna molecules and processes for producing lymphocyte function associated antigen-3 - Google Patents

Dna sequences recombinant dna molecules and processes for producing lymphocyte function associated antigen-3

Info

Publication number
SG49653A1
SG49653A1 SG1996002840A SG1996002840A SG49653A1 SG 49653 A1 SG49653 A1 SG 49653A1 SG 1996002840 A SG1996002840 A SG 1996002840A SG 1996002840 A SG1996002840 A SG 1996002840A SG 49653 A1 SG49653 A1 SG 49653A1
Authority
SG
Singapore
Prior art keywords
processes
associated antigen
function associated
lymphocyte function
dna sequences
Prior art date
Application number
SG1996002840A
Other languages
English (en)
Inventor
Barbara P Wallner
Timothy A Springer
Catherine Hession
Richard Tizard
Robert Mattaliano
Michael L Dustin
Original Assignee
Biogen Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG49653(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc, Dana Farber Cancer Inst Inc filed Critical Biogen Inc
Publication of SG49653A1 publication Critical patent/SG49653A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70528CD58
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG1996002840A 1987-06-03 1988-06-03 Dna sequences recombinant dna molecules and processes for producing lymphocyte function associated antigen-3 SG49653A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/057,615 US4956281A (en) 1987-06-03 1987-06-03 DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3

Publications (1)

Publication Number Publication Date
SG49653A1 true SG49653A1 (en) 1998-06-15

Family

ID=22011704

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996002840A SG49653A1 (en) 1987-06-03 1988-06-03 Dna sequences recombinant dna molecules and processes for producing lymphocyte function associated antigen-3

Country Status (11)

Country Link
US (1) US4956281A (de)
EP (1) EP0315683B1 (de)
JP (1) JP2659781B2 (de)
AT (1) ATE176502T1 (de)
AU (1) AU634464B2 (de)
CA (1) CA1340232C (de)
DE (1) DE3856301T2 (de)
HU (1) HU211627A9 (de)
MX (1) MX9202970A (de)
SG (1) SG49653A1 (de)
WO (1) WO1988009820A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340921A (en) * 1986-07-03 1994-08-23 T Cell Sciences, Inc. Γ, δT cell receptor and methods and detection
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US6461825B1 (en) * 1987-09-30 2002-10-08 Sanofi (Societe Anonyme) Immunometric assay kit and method applicable to whole cells
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
DE68929096T2 (de) 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
CA2049931A1 (en) * 1990-01-24 1991-07-25 Barbara P. Wallner Lfa-3 as a vaccine adjuvant
DE4008354A1 (de) * 1990-03-15 1991-09-19 Basf Ag Neues protein, seine herstellung und verwendung
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
ES2134762T3 (es) * 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
JP2560160B2 (ja) * 1990-08-20 1996-12-04 社団法人北里研究所 新規なdna塩基配列およびその用途
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
CA2081028C (en) * 1991-03-12 1999-12-14 Barbara P. Wallner Cd2 binding domain of lymphocyte function associated antigen 3
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
ES2169783T3 (es) * 1991-10-07 2002-07-16 Biogen Inc Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2.
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5856928A (en) * 1992-03-13 1999-01-05 Yan; Johnson F. Gene and protein representation, characterization and interpretation process
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) * 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
WO1996033217A1 (fr) * 1995-04-19 1996-10-24 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Proteine d'adhesion de cellules, agent immunosuppresseur contenant cette proteine et agent immunosuppresseur renfermant des cellules ainsi induites
SI0833934T2 (sl) * 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP4104704B2 (ja) * 1997-10-01 2008-06-18 シスメックス株式会社 自動分析装置用洗浄剤
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
HUP0103563A3 (en) * 1998-08-31 2004-04-28 Biogen Idec Ma Inc Cambridge Method of modulating memory effector t-cells and compositions
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) * 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
CA2454618C (en) * 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
EP1864691B1 (de) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modifizierte CEA-Nukleinsäure und entsprechende Expressionsvektoren
KR101021387B1 (ko) * 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
MXPA06008918A (es) * 2004-02-06 2007-03-07 Astellas Llc Metodos de tratamiento de trastornos de la piel.
EP1747291A2 (de) * 2004-05-04 2007-01-31 Genaissance Pharmaceuticals, Inc. Haplotyp-marker sowie deren verwendung zur bestimmung der reaktion auf eine behandlhung
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US9079947B2 (en) 2007-11-27 2015-07-14 The University Of British Columbia 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
CA2754741C (en) * 2009-03-11 2019-02-12 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
AU2012325604B2 (en) 2011-10-21 2017-08-03 Augurex Life Sciences Corp. Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3377363D1 (en) * 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4728927A (en) * 1984-09-28 1988-03-01 Aman James A Apparatus and method for performing comparison of two signals

Also Published As

Publication number Publication date
US4956281A (en) 1990-09-11
WO1988009820A1 (en) 1988-12-15
CA1340232C (en) 1998-12-15
EP0315683A1 (de) 1989-05-17
ATE176502T1 (de) 1999-02-15
JPH02501113A (ja) 1990-04-19
MX9202970A (es) 1992-07-01
EP0315683A4 (de) 1990-02-05
AU1955288A (en) 1989-01-04
DE3856301D1 (de) 1999-03-18
AU634464B2 (en) 1993-02-25
DE3856301T2 (de) 1999-07-15
HU211627A9 (en) 1995-12-28
HK1009291A1 (en) 1999-05-28
JP2659781B2 (ja) 1997-09-30
EP0315683B1 (de) 1999-02-03

Similar Documents

Publication Publication Date Title
SG49653A1 (en) Dna sequences recombinant dna molecules and processes for producing lymphocyte function associated antigen-3
AU2964489A (en) Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides
ZA81103B (en) Dna sequences ,recombinant dna molecules dna molecules and processes for producing human interferon -like polypeptides
GR3035856T3 (en) Hybrid immunoglobulins.
AU661696B2 (en) DNA sequences to target proteins to the mammary gland for efficient secretion
DE3165463D1 (en) Dna sequences, recombinant dna molecules and processes for producing human interferon-alpha like polypeptides
ATE193724T1 (de) Cd2 bindender bereich für das lymphocyten- funktion assoziierte antigen-3
NO864759D0 (no) Eutaryotiske fusjonsproteiner, fremstilling og anvendelse derav samt middel til gjennomfoering av fremgangsmaaten.
AU4644689A (en) Hybrid procoagulant proteins
EP0739350A4 (de) Fas-antigenbindender ligand
ZA86217B (en) Dna sequences,recombinant dna molecules and processes for producing human lipocortin-like polypeptides
AU606584B2 (en) DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
EP0091527A3 (de) DNS Sequenzen, rekombinante DNS Moleküle und Verfahren zur Herstellung von menschlichem Serum Albumin ähnlichen Polypeptiden
AU4219489A (en) Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
EP0273302A3 (en) Piezoelectric type lighter for use in lighting pipes
FI863626A7 (fi) DNA-sekvenssejä, yhdistelmä-DNA -molekyylejä ja menetelmiä ihmisen lip okortiinin kaltaisia polypeptidejä.
AU7733387A (en) Polypeptides of the rhinovirus strain HRV89 and the DNA molecules coding therefor
IL79797A (en) Expression dna sequence for use in e.coli
DE69332583D1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
HRP921091B1 (en) Dna sequences, recombinant dna molecules and processes for producing human fibroplast interferon-like polypeptides
MX9709455A (es) Polinucleotidos de adenosina-cinasa.
KE3669A (en) Dna sequences,recombinant dna molecules and processes for producing human interferon-alpha like polypeptides
ZA812189B (en) Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides
ZA886593B (en) Dna sequences,recombinant dna molecules and processes for producing soluble t4 proteins
IT8485664A0 (it) Procedimento per il trattamento di liquami di conceria con ricupero di torbide proteiche utilizzabili in zootecnia.